

**TFCP2L1 Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP13438b****Specification**

---

**TFCP2L1 Antibody (C-term) Blocking peptide - Product Information**Primary Accession [Q9NZI6](#)**TFCP2L1 Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 29842**Other Names**Transcription factor CP2-like protein 1, CP2-related transcriptional repressor 1, CRTR-1,  
Transcription factor LBP-9, TFCP2L1, CRTR1, LBP9**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP13438b was selected from the C-term region of TFCP2L1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**TFCP2L1 Antibody (C-term) Blocking peptide - Protein Information****Name** TFCP2L1**Synonyms** CRTR1, LBP9**Function**

Transcription factor that facilitates establishment and maintenance of pluripotency in embryonic stem cells (ESCs) (PubMed: <http://www.uniprot.org/citations/25215486> target="\_blank">25215486</a>, PubMed: <http://www.uniprot.org/citations/26906118> target="\_blank">26906118</a>). With KLF2, acts as the major effector of self-renewal that mediates induction of pluripotency downstream of LIF/STAT3 and Wnt/beta-catenin signaling (By similarity). Required for normal duct development in the salivary gland and kidney (By similarity). Coordinates the development of the kidney collecting ducts intercalated (IC) and principal (PC) cells, which regulate acid- base and salt-water homeostasis, respectively (By similarity). Regulates the expression of IC genes including subunits B1 and D2 of the V-ATPase complex, OXGR1, CA12, SLC4A1, AQP6 and IC-specific transcription factor FOXI1 (By similarity). Regulates also the

expression of JAG1 and subsequent notch signaling in the collecting duct (By similarity). JAG1 initiates notch signaling in PCs but inhibits notch signaling in ICs (By similarity). Acts as a transcriptional suppressor that may suppress UBP1-mediated transcriptional activation (By similarity). Modulates the placental expression of CYP11A1 (PubMed:<a href="http://www.uniprot.org/citations/10644752" target="\_blank">10644752</a>).

**Cellular Location**

Nucleus.

**Tissue Location**

Highly expressed in placental JEG-3 cells and very low levels of expression in non-steroidogenic cells. No expression was seen in adrenal NCI-H295A cells or in adrenal tissue

**TFCP2L1 Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**TFCP2L1 Antibody (C-term) Blocking peptide - Images****TFCP2L1 Antibody (C-term) Blocking peptide - Background**

TFCP2L1 is a transcriptional suppressor. May suppress UBP1-mediated transcriptional activation. Modulates the placental expression of CYP11A1.

**TFCP2L1 Antibody (C-term) Blocking peptide - References**

To, S., et al. PLoS ONE 5 (7), E11702 (2010) :Henderson, Y.C., et al. DNA Cell Biol. 27(2):71-79(2008) Hillier, L.W., et al. Nature 434(7034):724-731(2005) Huang, N., et al. Mol. Endocrinol. 19(2):409-420(2005) Rodda, S., et al. J. Biol. Chem. 276(5):3324-3332(2001)